Ratings Global Medical REIT Inc.

Equities

GMRE

US37954A2042

Market Closed - Nyse Other stock markets 01:30:02 22/06/2024 am IST			5-day change	1st Jan Change
8.81 ^USD	-4.76%		-2.33%	-20.63%

06/06	Global Medical REIT Keeps Q2 Dividend at $0.21 a Share, Payable July 9 to Holders of Record June 21	MT
06/06	Global Medical REIT Inc. Declares 2024 Second Quarter Common Dividend, Payable on July 9, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company is one of the best yield companies with high dividend expectations.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company sustains low margins.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 391.56 times its estimated earnings per share for the ongoing year.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialized REITs

	1st Jan change	Capi.	ESG Refinitiv
GLOBAL MEDICAL REIT INC.	-20.63%	578M	C
WELLTOWER INC.	+13.47%	61.18B	A-
VENTAS, INC.	+1.16%	20.37B	A-
HEALTHPEAK PROPERTIES, INC.	-2.83%	13.54B	A
OMEGA HEALTHCARE INVESTORS, INC.	+7.70%	8.16B	B
HEALTHCARE REALTY TRUST INCORPORATED	-5.86%	6.08B	B-
CARETRUST REIT, INC.	+11.26%	3.6B	C-
SABRA HEALTH CARE REIT, INC.	+2.59%	3.39B	C+
NATIONAL HEALTH INVESTORS, INC.	+19.52%	2.9B	C-
MEDICAL PROPERTIES TRUST, INC.	-2.24%	2.88B	C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes